A phase i trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: Evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin

Investigational New Drugs

Volumn 32, Issue 6, 2014, Pages 1269-1277

  Brana, Irene ^a   Ocana, Alberto ^a   Chen, Eric X ^a   Razak, Albiruni R A ^a   Haines, Christine ^a   Lee, Carol ^b   Douglas, Sarah ^a   Wang, Lisa ^a   Siu, Lillian L ^a   Tannock, Ian F ^a,b   Bedard, Philippe L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Autophagy; Doxorubicin; Drug distribution; Pantoprazole

Indexed keywords

DOCETAXEL; DOXORUBICIN; PANTOPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PENETRATION; DRUG RESPONSE; DYSGEUSIA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEPATITIS; HUMAN; HYPOTENSION; LEUKOPENIA; LUNG INFECTION; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; TOOTH INFECTION; TUMOR BIOPSY; VOMITING; CANCER STAGING; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; NEOPLASMS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

EID: 84927512782     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0159-5     Document Type: Article

References (38)

1. Jain RK (1994) Barriers to drug delivery in solid tumors. Sci Am 271:58-65
2. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583-592. doi: 10.1038/nrc1893
3. Di Paolo A, Bocci G (2007) Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification. Curr Oncol Rep 9:109-114
4. Lankelma J, Dekker H, Fernández Luque R, Luykx S, Hoekman K, Pvd V, van Diest PJ, Pinedo HM (1999) Doxorubicin gradients in human breast cancer. Clin Cancer Res 5:1703-1707
5. Kyle AH, Huxham LA, Yeoman DM, Minchinton AI (2007) Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res 13:2804-2810. doi: 10.1158/1078-0432.ccr-06-1941
6. Tannock IF, Rotin D (1989) Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49:4373-4384
7. Simon S, Roy D, Schindler M (1994) Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci 91:1128-1132. doi: 10.1073/pnas.91.3.1128
8. Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK (2002) Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 8:1284-1291
9. Rotin D, Robinson B, Tannock IF (1986) Influence of hypoxia and an acidic environment on the metabolism and viability of cultured cells: potential implications for cell death in tumors. Cancer Res 46:2821-2826
10. Gillies RJ, Liu Z, Bhujwalla Z (1994) 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am J Physiol Cell Physiol 267:C195-C203
11. Mahoney BP, Raghunand N, Baggett B, Gillies RJ (2003) Tumor acidity, ion trapping and chemotherapeutics: I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 66:1207-1218. doi: 10.1016/S0006-2952(03)00467-2
12. Altan N, Chen Y, Schindler M, Simon SM (1998) Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med 187:1583-1598. doi: 10.1084/jem.187.10.1583
13. Levine B (2007) Cell biology: autophagy and cancer. Nature 446:745-747
14. White E (2012) Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 12:401-410
15. Sivridis E, Koukourakis MI, Zois CE, Ledaki I, Ferguson DJ, Harris AL, Gatter KC, Giatromanolaki A (2010) LC3A-positive light microscopy detected patterns of autophagy and prognosis in operable breast carcinomas. Am J Pathol 176:2477-2489
16. Sivridis E, Koukourakis MI, Mendrinos SE, Karpouzis A, Fiska A, Kouskoukis C, Giatromanolaki A (2011) Beclin-1 and LC3A expression in cutaneous malignant melanomas: a biphasic survival pattern for beclin-1. Melanoma Res 21:188-195
17. Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K, Eddy S, Goodin S, White E, DiPaola RS (2010) Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 70:1388-1394. doi: 10.1002/pros.21172
18. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, Bause A, Li Y, Stommel JM, Dell'Antonio G, Mautner J, Tonon G, Haigis M, Shirihai OS, Doglioni C, Bardeesy N, Kimmelman AC (2011) Pancreatic cancers require autophagy for tumor growth. Genes Dev 25:717-729. doi: 10.1101/gad.2016111
19. Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin IM, Walsh JH, Beg M, Bochenek W, Metz DC (2000) Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 118:696-704
20. Sabolic I, Brown D, Verbavatz JM, Kleinman J (1994) H(+)-ATPases of renal cortical and medullary endosomes are differentially sensitive to Sch-28080 and omeprazole. Am J Physiol Ren Physiol 266:F868-F877
21. Nishi T, Forgac M (2002) The vacuolar (H+)-ATPases-nature's most versatile proton pumps. Nat Rev Mol Cell Biol 3:94-103. doi: 10.1038/nrm729
22. Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Iessi E, Parmiani G, Arancia G, Belardelli F, Fais S (2004) Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 96:1702-1713. doi: 10.1093/jnci/djh305
23. Lee CM, Tannock IF (2006) Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br J Cancer 94:863-869. doi: 10.1038/sj.bjc.6603010
24. De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, Federici C, Perdicchio M, Matarrese P, Lugini L, Nilsson A, Fais S (2007) Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 67:5408-5417. doi: 10.1158/0008-5472.can-06-4095
25. Patel KJ, Lee CM, Tan Q, Tannock IF (2013) Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res. doi: 10.1158/1078-0432.ccr-13-012810.1158/1078-0432.ccr-13-0128
26. Ouar Z, Bens M, Vignes C, Paulais M, Pringel C, Fleury J, Cluzeaud F, Lacave R, Vandewalle A (2003) Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells. Biochem J 370:185-193. doi: 10.1042/bj20021411
27. Udelnow A, Kreyes A, Ellinger S, Landfester K, Walther P, Klapperstueck T, Wohlrab J, Henne-Bruns D, Knippschild U, Wurl P (2011) Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. PLoS ONE 6:e20143
28. Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101:708-720. doi: 10.1093/jnci/djp079
29. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247. doi: 10.1016/j.ejca.2008.10.026
30. Brenner DE, Galloway S, Cooper J, Noone R, Hande KR (1985) Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography. Cancer Chemother Pharmacol 14:139-145
31. Fung AS, Jonkman J, Tannock IF (2012) Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel. Neoplasia 14:324-334
32. Shi S, Klotz U (2008) Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 64:935-951. doi: 10.1007/s00228-008-0538-y
33. Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53:555-561
34. Rushing DA, Piscitelli SC, Rodvold KA, Tewksbury DA (1993) The disposition of doxorubicin on repeated dosing. J Clin Pharmacol 33:698-702
35. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF (2005) The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11:8782-8788
36. Patel KJTO, Tannock IF (2013) Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother Phamacol 72:127-138. doi: 10.1007/s00280-013-2176-z
37. Saggar JK, Fung AS, Patel KJ, Tannock IF (2013) Use of molecular biomarkers to quantify the spatial distribution of effects of anticancer drugs in solid tumors. Mol Cancer Ther 12:542-552
38. Agulnik M, Oza AM, Pond GR, Siu LL (2006) Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol 24:4801-4807. doi: 10.1200/jco.2005.03.4496